Lab21 Ltd.

Lab21 is a rapidly growing healthcare diagnostics business. The company’s vision is of providing personalised diagnostic testing for disease identification, disease predisposition and personalised medicine to protect people from the health problems of tomorrow. We believe that ‘prevention is better than cure’ and aim to provide information that helps to protect people from their health problems of tomorrow. The main business is focused on two trading divisions: • Molecular diagnostic testing services for patients needing diagnosis and optimised treatment, in areas such as cancer and virology, where Lab21 offers a wide range of services including handling of infectious samples in its Category 3 containment facilities. Lab21 is also a market leader in the provision and development of companion diagnostic services, working closely with major pharma companies. The Lab21 reference lab is fully accredited for handling patient and clinical trial samples and the company has developed excellent logistic services to transport samples from many parts of the world. As part of its reference lab service the company also has considerable experience in the development and commercialisation of new biomarker assays using its own or partner IP. • Proprietary manufactured antibody and antigen-based products, for infectious diseases such as syphilis, CMV, TB, CMV and malaria which are sold into worldwide blood banking and diagnostic product markets. The current portfolio is continually expanding with a range of proprietary new and improved immuno- and molecular diagnostic products that are sold into 100+ countries through a combination of direct and indirect distribution channels. Lab21 has four UK based sites and will soon have its US headquarters based in South Carolina, USA. 2009 has seen the company’s revenues triple and expects this growth to continue through a combination of organic and acquisitive growth.